Key result
ACE inhibitors linked to ~5-fold higher 1-year survival in scleroderma renal crisis.
Why the study?
The study aimed to determine the outcome of scleroderma renal crisis before and after the availability of angiotensin converting enzyme (ACE) inhibitors.
Does therapy with ACE inhibitors improve survival and renal outcomes in patients with systemic sclerosis and scleroderma renal crisis?
Cohort (n=108)
No
Does therapy with ACE inhibitors improve survival and renal outcomes in patients with systemic sclerosis and scleroderma renal crisis?
Answers are grounded in this paper and cite their sources.
ACE inhibitor therapy dramatically improves 1-year survival from 15% to 76% and enables successful discontinuation of dialysis in patients with scleroderma renal crisis.
Objective To determine the outcome of scleroderma renal crisis before and after the availability of angiotensin converting enzyme (ACE) inhibitors. Design Evaluation of a large cohort of patients with systemic sclerosis and renal crisis who were followed prospectively. Setting University scleroderma center. Patients One hundred and eight patients who had scleroderma renal crisis between 1972 and 1987. Intervention ACE inhibitors. Measurements and main results Therapy with ACE inhibitors has dramatically improved the survival of patients with scleroderma renal crisis (1-year survival, 15% without and 76% with ACE inhibitors; P less than 0.001). However, 24 (44%) of 55 patients with scleroderma renal crisis who were treated with ACE inhibitors died early or required permanent dialysis. Older age, male sex, an initial serum creatinine level of more than 270 mumol/L, inadequately controlled blood pressure, and congestive heart failure were associated with these poor outcomes, but only older age and congestive heart failure were significant in a multivariate logistic regression analysis. Eleven of twenty patients (55%) who survived dialysis more than 3 months and continued to receive therapy with ACE inhibitors were able to discontinue dialysis after 3 to 15 months compared with 0 of 15 dialysis patients who did not receive ACE-inhibitor therapy (P = 0.002). Conclusions Patients with systemic sclerosis who develop hypertension should be treated with an ACE inhibitor. Improved survival and successful discontinuation of dialysis are possible when ACE inhibitors are used to treat scleroderma renal crisis.
No takes yet. Share an insight, caveat, or question.
Virginia Steen (1990) conducted a cohort in Scleroderma renal crisis in systemic sclerosis (n=108). Angiotensin converting enzyme (ACE) inhibitors vs. No ACE inhibitors was evaluated on 1-year survival (p=<0.001). ACE inhibitor therapy improved 1-year survival in patients with scleroderma renal crisis compared with no ACE inhibitor therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: